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Summary: 17-Ketosteroids were determined by gas chromatography in twenty four-hour urine samples from
62 hirsute females. The method permitted the determination of androsterone (A), aetiocholanolone (E) and
dehydroepiandrosterone (D). Elevated concentrations of one or more of these metabolites were detected in
81% of the samples.
Two main patterns of hyperandrogenicity were observed:
1) Hyper A + E (27%) and
2) Hyper A (26%);
Elevated AD, AED, D, ED or E were less common, but in total these patterns comprised another 28%.
The plasma testosterone and total urinary 17-ketosteroid concentrations were elevated in only 21% and 23%
of the samples, respectively. _
Thirty two out of 33 patients with elevated urine metabolites showed significant suppression following
dexamethasone administration (2 mg/day during 6 days). Thus, dexamethasone suppressable hyperandrogen-
icity was predomimant in this group of hirsute females. Elevations of urinary androsterone and aetiocholan-
olone are probably contingent on the relative activities of 5 - and Sß-reductases1) in the presence of increased
androstenedione secretion. Elevations of urinary dehydroepiandrosterone suggest decreased adrenal cortical
3ß-hydroxysteroid dehydrogenase1) activity. Thus, fractionation of urinary 17-ketosteroids seems to be an
effective test in the evaluation of hirsutism.
') Enzymes Introduction
3a-Hydroxysteroid dehydrogenase:
3ot-Hydroxysteroid: NAD(P)+-oxidoreductase (EC 1.1.1.50) A relatively undervalued diagnostic tool for establish-
3ß-Hydroxysteroid dehydrogenase: jng .^  presence of excess production of androgens is
3ß-Hydroxysteroid: NAD(?)+-oxidoreductase (EC 1.1.1.51)
 r ,. ,. r ,, . 4n , . , · , ·5oc-Reduciase: / fractionation of the urinary 17-ketosteroids, with
3a-Hydroxy-5a-steroid:NAD'h-3-oxidorediictase measurement of androsterone, aetiocholanolone, and
(EC 1.1.1.151) dehydroepiandrosterone. The usefulness of this tech-
taJIyd^ ^ in evaluating patients with clomiphene-resistant
(EC 1.1.1.152) anovulation has been previously reported (1).
J. Clin. Chem. Clin. Biochem. / Vol. 27,1989 / No. l
28 Shapiro et al.: 17-ketosteroid fractionation in hirsutism
We have now used this procedure in conjunction with
dexamethasone and human chorionic gonadotropin
administration in the evaluation of females with pre-
dominant hirsutism.
Several different patterns of hyperandrogenicity were
detected involving different combinations of the three
androgens androsterone, aetiocholanolone or dehy-
droepiandrosterone. This report presents and dis*
cusses the significance of these fractionation patterns
s applied to the urinary 17-ketosteroids of 62 patients
with hirsutism, 33 of whom also completed the com-
bined hormone administration regimen.
Materials and Methods
Pat ients populat ion
Sixty tvvo hirsute females (age r nge 20 — 35 years) were ex-
amined in the endocrine outpatient clinic. Thirty had associated
menstrual disorders, and 18 had acne. Only one patient com-
plained of difllculties vvith conception. Hirsutism was graded
in 4 stages (2).
Laboratory methods
The 24-hour urinary 17-ketosteroids were measured by a chem-
ical technique (3). For determination of androsterone, aetio-
cholanolone and dehydroepiandrosterone, urinary 17-ketoste-
roids were fractionated by gas chromatography by the method
of Gould et al. (4). Plasma concentrations of hormones were
measured using commercial radioimmunoassay kits: testoster-
one — Serono Diagnostics; prolactin, luteinizing hormone and
follicle stimulating hormone — International CIA Sorin (Sal-
uggia, Cedex).
All data are given s mean ± Standard error mean.
Dynamic endocrine tests
Dexamethasone was administered orally (2mg/day during 6
days). Human chorionic gonadotropin, 2500 units, was injected
on days 4, 5 and 6. The urinary 17-ketosteroids were fraction-
ated befofe dexamethasone administration, on day 3 of dexa-
methasone administration and on day 6 during dexamethasone
and human chorionic gonadotropin administration (5). This
procedure was completed for thirty six patients.
Results
Fifty of the 62 females (81%) showed elevations of
one or m re of the individual androgens (androster-
one), (aetiocholanolone) or (dehydroepiandrosterone)
(references values: androsterone 2.1 + 0.7 mg/24 h;
aetiocholanolone l .9 + 0.8 mg/24 h; dehydroepi^
androsterone 0.9 + 0.3 mg/24 h).
Two mairi patterns of abnormal androgen secretion
were observed:
1) Hyper AE, 17 patients (27%): androsterone 5.4
± 0.4 mg/24 h; aetiocholanolone 3.8 ± 0.4 mg/24 h;
2) Hyper A, 16 patients (26%): androsterone 4.4
± 0.3 mg/24 h (fig. 1).
Other minor patterns observed were:
AD, 5 patients (8%): androsterone 5.6 ± 1.0 mg/
24h;
dehydroepiandrosterone 2. l + 0.4 mg/24 h;
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AED: androsterone 6.7 ± 0.2 mg/24 h; aetiocholan-
olone4.1 ± 0.5 mg/24 h; dehydroepiandrosterone 3. l
± 0.5 mg/24 h and
D: dehydroepiandrosterone 2.6 ± 0.4 mg/24 h with
four patients (6%) each;
ED: aetiocholanolone 5.1 ±0.1 mg/24 h; dehydro-
epiandrosterone 2.35 ±0.1 mg/24 h and
E: aetiocholanolone 4.75 ±0.1 mg/24 h, with two
patients (3%) each (fig. 1).
The extent of the increase of androgen concentration
did not correlate with the stage of hirsutism, s pre-
viously reported by other workers (5).
In contrast, the total urinary 17-ketosteroids were
elevated in only 14 patients (23%). Plasma testoster-
one was mildly elevated in 13 patients (21%) with
concentrations of 13 ± 4 ng/1 (normal: < 10 ng/1).
Plasma prolactin, luteinizing hormone and follicle
stimulating hormone concentrati ns were appropriate
for the respective menstrual states in all patients.
Thirty two out of 33 (97%) patients receiving both
dexamethasone and human chorionic gonadotropin
showed significant suppression of the elevated andro-
gen concentrations following dexamethasone admin-
istration. In the Hyper AE group (12 patients), the
concentration of androsterone dropped to 1.5 ± 0.19
mg/24 h and that of aetiocholanolone to 0.92 ± 0.1
mg/24 h after dexamethasone (fig. 2). The androster-
one concentrations of the Hyper A group (10 patients)
feil to 1.2 ±0.16 mg/24 h. The 10 remaining patients
in the other groups who were receiving dexametha-
sone all showed significant suppression of their re-
spective elevated androgens (fig. 2).
Two patients in the Hyper AE group showed eleva-
tions of 50% or niore of both androsterone and
aetiocholanolone following administration of human
chorionic gonadotropin. In a single patient with Hy-
per A, the level of androsterone was not suppressed
with dexamethasone, and it rose from 3.9 to 6.1 mg/
24h following chorionic gonadotropin administra-
tion.
Discussion
Fractionation of 17-ketosteroids demonstrated the
presence of hyperandrogenicity in 81% of the pa-
tients, whereas total urinary 17-ketosteroids and
plasma testosterone levels were elevated in only 23%
and 21%, respectively.
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Fig. 2. Fractionation of urinary 17-ketosteroids: androsterone (A)j aetiocholanolone (E) and dehydroepiandrosterone (D) with
dexamethasone suppression. The first panel represents the upper limits of normal in non-hirsute patients ( s in fig. 1).
Androgen levels before (o) and following (·) administration of dexamethasone 2 mg/day for 6 days are presented for
each group (21 patients). The mean ± Standard error mean are listed for Groups AE (12 patients); A (10 patients); AD
(2 patients); AED (4 patients) and ED (2 patients). In Groups D and E individual points represent single patients.
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The varying palterns of hyperandrogenicity detected
by gas chromatography in hirsute females are of in-
terest. Dehydropiandrosterone is predominantly of
adrenal cortical origin (6). The levels of urinary de-
hydroepiandroslerone are inversely proportional to
adrenal cortical 3ß-hydroxysteroid dehydrogenase ac-
tivity. Thus, elevation of dehydroepiandrosterone sug-
gests reduced adrenal 3ß-hydroxysteroid dehydrogen-
ase activity (7, 8). Bongiovanni (8) has also demon-
strated that mild deficiencies of 3ß-hydroxysteroid
dehydrogenase may be common in hirsute women.
Fifteen of our patients (24%) showed elevated dehy-
droepiandrosterone, suggesting an adrenal origin for
this metabolite (flg. 1).
The origin of the elevated urinary androsterone and
aetiocholanolone remains controversial. Both andro-
sterone and aetiocholanolone are derived predomi-
nantly from androstenedione (9). Androstenedione is
secreted from both the adrenal cortex and the ovary
(6, 10).
Testosterone and androstenedione are metabolized by
reduction of ttie C3 ketone group (mainly by 3 -
hydroxysteroid dehydrogenase) and the C4-ene by 5 -
and 5ß-reductases (9).
The 3a-5a-derivative is androsterone, whereas the 3 -
5ß-derivative is aetiocholanolone. Variations in the
relative activity of the 5 - and 5ß-reductases will be
reflected in the relative amounts of androsterone and
aetiocholanolone secreted.
The Hyper A pattern suggests enhanced 5a-reductase
activity, while the Hyper E pattern suggests enhanced
5ß-reductase activity; in the Hyper AE pattern the
activities of the 5 - and 5ß-reductases are almost
comparable.
The Hyper A pattern was seen in 16 (26%) and the
Hyper E pattern in 2 (3%) of the patients. Elevations
of androsterone, alone or in combination with other
metabolites, were seen in 42 patients (68%). Similarly,
aetiocholanolone was elevated in a total of 25 patients
(40%). An increase in 5a-reductase activity appears,
therefore, to be a factor to be taken into account in
a significant proportion of these hirsute women. In-
deed, elevated 5a-reductase activity has been dem-
onstrated in the skin of hirsute females (11).
Many studies have presented evidence for either an
adrenal (8, 12, 13), ovarian (14-17) or mixed ovar-
ian-adrenal (18) source of androgen production in
hirsute patients. The most convincing evidence for
ovarian suppression with dexamethasone administra-
tion was derived from ovarian and adrenal venous
catheterization studies (16). Although concentrations
of testosterone and androstenedione were higher in
the ovarian veins, 20 out of 44 patients exhibited 50%
suppression of plasma androgens after dexametha-
sone administration (14).
These studies suggest the existence of an ovarian
androgen-producing cell with sensitivity to a pituitary
hormone, similar to the postulated adrenal androgen-
stimulating hormone, which, indeed, displays a glu-
cocorticoid feedback mechanism (19J.
In the overwhelming majority of our patients, andro-
gen concentrations were significantly decreased föl-
lowing the administration öf dexamethasone, with no
response to human chorionic gonadotropin. These
findings are also quite compatible with the presence
of an androgen-secreting cell in either the adrenals of
ovaries, with depeiidence on andrenocorticotropic
hormone or another pituitary androgen-stimulating
hormone. Sixty percent of the patients with elevated
androgens responded with varying degrees .of dimin-
ished rates of hair growth. These results are compa-
rable to those reported by Moore et al. (13). The lack
of correlation between the response to treatment and
the results of short-term dynamic tests has been de-
scribed previously (13, 20).
The results in this study should be contrasted with
the urinary steroid profiles reported in 24 other fe-
males with idiopathic hirsutism (21): ten to hundred-
fold increases in the excretion of dehydroepiandro-
sterone were demonstrated in over 50% of these pa-
tients. Dehydroepiandrosterone levels were süp-
pressed much more than other steroids following
administration of dexamethasone. In our series of
patients with idiopathic hirsutism elevations of an-
drosterone and aetiocholanolone, rather than dehy-
droepiandrosterone, were most frequent. Elevations
of dehydroepiandrosterone in combinations with an-
drosterone and aetiocholanolone were seen in 23%.
Isolated elevation of dehydroepiandrosterone was
seen in only 6% of the group. Following dexameth-
asone administration, suppression of all steroid me-
tabolites was noted rather than that of dehydroepian-
drosterone alone.
The excretion of dehydroepiandrosterone is < l .0 mg/
24 h in normal women, with a ränge from 0.1 to 1.0
mg/24 h. Elevation of dehydroepiandrosterone has
been observed in stress in normal subjects (22). This
raises the question of whether the elevations of de-
hydroepiandrosterone noted in our hirsute females
were manifestations of stress. This seems unlikely,
since the elevations of dehydroepiandrosterone were
accompanied by elevations of androsterone or ae-
tiocholanolone in all büt 2 of our subjects. It therefore
appears that all these steroid metabolites showing
elevated levels are associated with the presence of
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hirsutism. When dehydroepiandrosterone is the only
urinary 17-ketosteroid excreted in elevated quantities,
stress may be an alternative explanation, rather than
reduced adrenal 3ß-hydroxysteroid dehydrogenase ac-
tivity. The possibility of an enzymatic block can be
verified by Stimulation with adrenocorticotropic hor-
mone (8).
In summary, fractionation of the 17-ketosteroids by
gas chromatography seems to be an efficient method
for detecting the presence of hyperandrogenicity and
in assessing its origin. When used in conjunction with
dynamic studies, it can detect the presence of adreno-
corticotropic hormone or human chorionic gonado-
tropin dependency. Elevated concentrations of dehy-
droepiandrosterone may indicate the presence of a
3ß-hydroxysteroid dehydrogenase deficiency äs the
basis for hyperandrogenicity.
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